This [Section 9.3] will not apply to any Tax claims, which are governed by [Section 6.13(d)].

This [Section 9.05] shall not apply to Taxes other than any Taxes that represent Liabilities arising from any non-Tax claim.

This [Section 9.03] shall survive any termination of this Agreement, the termination or assignment of the Commitments and the repayment of all outstanding Loans.

Nothing in this [Section 9.20] will constitute a waiver or release of any claim of the Administrative Agent hereunder arising from any Payment Recipient’s receipt of an Erroneous Payment.

Anything in this [Section 9.2] to the contrary notwithstanding, if any Conduit Investor enters into agreements for the acquisition of interests in receivables from one or more Other SPVs, such Conduit Investor shall allocate the liability for any amounts under this [Section 9.2] which are in connection with a Program Support Agreement or the credit or liquidity support provided by a Program Support Provider (“Additional Costs”) to the SPV and each Other SPV; provided, however, that if such Additional Costs are attributable to the SPV, any Originator or the Master Servicer and not attributable to any Other SPV, the SPV shall be solely liable for such Additional Costs or if such Additional Costs are attributable to Other SPVs and not attributable to the SPV, any Originator or the Master Servicer, such Other SPVs shall be solely liable for such Additional Costs.

[Section 9.5.1.1] of the Agreement is hereby amended by appending the following to the end thereof:

[Section 9.5.2] of the Agreement is hereby amended by appending the following to the end thereof: “Novartis hereby acknowledges and agrees that Surface has not granted to Novartis any licenses or rights under the Surface Technology to Research, Develop, Manufacture or Commercialize any Adimab Diagnostic Product (as defined in the Adimab Agreement) for a Licensed Target other than solely for the purposes of Research, Development or Commercialization of therapeutic or prophylactic Licensed Products that Specifically Binds to such Licensed Target in accordance with the terms and conditions of this Agreement.”

[Section 9.4(f)] of the Credit Agreement is hereby amended by deleting therein the words “[Reserved]” and inserting in lieu thereof the words “Liens granted by Cove Point on its bank accounts and reserve funds (and nonrecourse to the Borrower) in connection with any Indebtedness of Cove Point so long as the Borrower does not own, directly or indirectly, a majority of the common equity interests of Cove Point”.

[Section 9.5(b)(ii)] of the Credit Agreement is hereby amended by deleting therein the words “Cove Point incurred prior to completion of the Liquefaction Project in an aggregate principal amount not to exceed ​ at any time outstanding” and inserting in lieu thereof the words “Cove Point so long as such Indebtedness is nonrecourse to the Borrower and the Borrower does not own, directly or indirectly, a majority of the common equity interests of Cove Point”.

[Section 9.18(b)] of the Credit Agreement is hereby amended and restated in its entirety to read in full as follows: